Antivirulence drugs are a promising avenue to revitalize the antimicrobial drug-development pipeline, and it has been claimed that such compounds will generate much weaker selection for resistance than traditional antibiotics. Sam P. Brown and colleagues examine this claim and argue that, although resistance to antivirulence drugs may emerge, the crucial factor is whether or not this resistance will spread.
- Richard C. Allen
- Roman Popat
- Sam P. Brown